Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function

We have adopted this International Scientific Guideline - CPMP/EWP/2339/02

Last updated

20 August 2024

About this guideline

Overseas effective date: 1 August 2005

Categories: Clinical efficacy and safety | Clinical pharmacology and pharmacokinetics

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

Product types